Arbutus Biopharma Corp (ABUS)
2.98
+0.09
(+3.11%)
USD |
NASDAQ |
May 17, 16:00
2.985
0.00 (0.00%)
After-Hours: 20:00
Arbutus Biopharma Research and Development Expense (Annual): 73.70M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 73.70M |
| December 31, 2022 | 84.41M |
| December 31, 2021 | 65.50M |
| December 31, 2020 | 49.34M |
| December 31, 2019 | 57.60M |
| December 31, 2018 | 57.93M |
| December 31, 2017 | 62.68M |
| December 31, 2016 | 61.25M |
| December 31, 2015 | 51.50M |
| December 31, 2014 | 38.71M |
| December 31, 2013 | 21.46M |
| December 31, 2012 | 18.04M |
| December 31, 2011 | 20.13M |
| Date | Value |
|---|---|
| December 31, 2010 | 22.13M |
| December 31, 2009 | |
| December 31, 2008 | 13.25M |
| December 31, 2007 | |
| December 31, 2006 | 4.526M |
| December 31, 2005 | 8.763M |
| December 31, 2004 | 22.32M |
| December 31, 2003 | 23.71M |
| December 31, 2002 | 23.06M |
| December 31, 2001 | 12.73M |
| December 31, 2000 | 7.457M |
| December 31, 1999 | 7.746M |
| December 31, 1998 | 8.651M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
49.34M
Minimum
2020
84.41M
Maximum
2022
66.11M
Average
65.50M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Moderna Inc | 4.845B |
| Pfizer Inc | 10.68B |
| Regeneron Pharmaceuticals Inc | 4.439B |
| Chimerix Inc | 68.79M |
| Karyopharm Therapeutics Inc | 138.75M |